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journal.publications.chestneDuring the past decade, there has been increasing evidence that the small airways (ie,
airways < 2 mm in internal diameter) contribute substantially to the pathophysiologic and
clinical expression of asthma and COPD. The increased interest in small airways is, at least in
part, a result of innovation in small-particle aerosol formulations that better target the distal
lung and also advanced physiologic methods of assessing small airway responses. Increasing
the precision of drug deposition may improve targeting of specific diseases or receptor loca-
tions, decrease airway drug exposure and adverse effects, and thereby increase the efficiency
and effectiveness of inhaled drug delivery. The availability of small-particle aerosols of corti-
costeroids, bronchodilators, or their combination enables a higher total lung deposition and
better peripheral lung penetration and provides added clinical benefit, compared with large-
particle aerosol treatment. However, a number of questions remain unanswered about the
pragmatic approach relevant for clinicians to consider the role of small airways directed therapy
in the day-to-day management of asthma and COPD. We thus have tried to clarify the di-
lemmas, confusion, and misconceptions related to small airways directed therapy. To this end,
we have reviewed all studies on small-particle aerosol therapy systematically to address the
dilemmas, confusion, and misconceptions related to small airways directed therapy.
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TABLE 1 ] Drug Particle Size and Inhaler Type of Most
Frequently Prescribed ICS, LABA, LAMA,
and ICS/LABA Formulations
ICS Inhaler Type MMAD,a mm
Fluticasone
propionate
Diskus DPI 5.4
Fluticasone furoate Ellipta DPI 3.0-3.9
Fluticasone
propionate
Suspension HFA
pMDI
2.4
Budesonide Turbuhaler DPI 4.0
BDP Suspension HFA
pMDI
4.1
BDP Solution HFA pMDI 1.1
Ciclesonide Solution HFA pMDI 1.1
Flunisolide Solution HFA pMDI 1.2
LABA
Formoterol Solution HFA pMDI 1.2
Salmeterol Suspension HFA
pMDI
2.8
Indacaterol Breezhaler DPI 3.2
Vilanterol Ellipta DPI 1.8-2.5
LAMA
Tiotropium Soft mist inhaler 2.0
HandiHaler DPI 3.9
Aclidinium Genuair DPI 2.4
Glycopyrronium Breezhaler
DPI
2.8
ICS/LABA
Formoterol/BDP Solution HFA
pMDI
1.5
Formoterol/BDP NEXThaler DPI 1.5
Salmeterol/
fluticasone
propionate
Suspension HFA
pMDI
2.7
Salmeterol/
fluticasone
propionate
Diskus DPI 3.5
Formoterol/
budesonide
Turbuhaler DPI 3.0
Formoterol/
fluticasone
propionate
Suspension HFA
pMDI
3.15-3.52
BDP ¼ beclomethasone dipropionate; DPI ¼ dry powder inhaler; HFA ¼
hydrofluoroalkane; ICS ¼ inhaled corticosteroid; LABA ¼ long-acting
b2-adrenergic agonist; LAMA ¼ long-acting muscarinic antagonist;
MMAD ¼ mass median aerodynamic diameter; pMDI ¼ pressurized
metered-dose inhaler.
aDrug particle size is expressed as MMAD. (MMAD data are adapted from
Usmani,14,15 Chapman et al,16 Colthorpe et al,17 Lock et al,18 and Labiris et al.20)generations eight to 232 and are a significant component
of obstructive airway disease. Emphysema classically
involves the terminal bronchioles,3 but it is increasingly
recognized that asthma also involves small airways,4,5
not only in patients with severe asthma6 but also in
those with milder disease.7 Distal airway inflammation
and dysfunction also have been demonstrated in distinct
clinical asthma phenotypes,8 such as nocturnal
asthma,9,10 exercise-induced asthma,11 and allergic
asthma.12 These phenotypes support the targeting of
inhaled drug therapy toward the small airways.
Most inhaled therapies do not reach the small airways
sufficiently.13-18 Although the drug particle size pattern
may vary markedly among inhalers, conventional
pressurized metered-dose inhalers (pMDIs) and most
dry powder inhalers (DPIs) emit drug particles too large
to target the small airways effectively (Table 1). Overall,
these aerosol devices deposit approximately 20% of the
drug dose in the lungs,19 with a high proportion of the
drug being deposited in the oropharynx, which can
cause local and systemic effects through gastrointestinal
absorption.20 However, technological advances in device
engineering and drug formulation have led to a new
generation of inhalers emitting small-particle drug
aerosol at slower velocities, with enhanced lung
deposition (w 50%) and, most importantly, more
effective aerosol penetration into the lung periphery.13-18
These new inhalers and drug formulations include
solution-based hydrofluoroalkane (HFA)-propelled
pMDIs delivering aerosols of inhaled corticosteroid
(ICS)—namely, beclomethasone dipropionate (BDP),
ciclesonide, and flunisolide; long-acting b2-adrenergic
bronchodilators (LABAs)—namely, formoterol; and
ICS/LABA fixed-dose combinations—namely, BDP/
formoterol. Furthermore, a multidose DPI (NEXThaler,
Chiesi, Italy) delivering a small-particle ICS/LABA drug
combination,21 as well as a novel device category—
namely, a soft mist inhaler (Boehringer Ingelheim),
delivering small-particle aerosols of long-acting
bronchodilators—also have been developed.22
Because of the high drug deposition in the lungs and
better targeting of the small airways, these new inhaler
devices in theory should be more effective for treating
the peripheral lung compartment in patients with
asthma and COPD. Studies in patients with
asthma7,13,14,23-25 and COPD26 show larger
improvements in markers of small airway function with
small-particle aerosols, compared with large-particle
aerosols, and lend support to this theory. However,
several questions still need clarification. For instance, the1346 Recent Advances in Chest Medicineoptimal particle size for an inhaled drug to reach and
deposit into the small airways effectively has not been
defined clearly, as reflected by the different terms and[ 1 5 1 # 6 CHES T J U N E 2 0 1 7 ]
sizes (ie, submicron,27 < 1 mm; ultrafine,28 1.1 mm;
extrafine,21 1.5 mm2) used to describe the finer small-
particle aerosols delivered by these inhalers. In
agreement with the literature,13-15 we define “small
particles” as those with a size expressed as mass median
aerodynamic diameter (MMAD)—the aerodynamic
diameter above and below which 50% of the mass
resides20—of < 2 mm. We also call particles < 1 mm
“submicron” and those > 2 mm “large” or “coarse,” as
has been used by other authors.27,29
The aim of this article is to address six clinical questions
related to the use of small-particle aerosols that are
relevant to practicing health-care professionals in their
day-to-day clinical practice. These questions were
selected by means of consensus by the members of
the Aerosol Drug Management Improvement Team
(www.admit-inhalers.org), a working group of
physicians with combined clinical and research expertise
on the topic of inhaled therapy for respiratory diseases.
The six questions listed are not meant to be hierarchical
or all-inclusive, but, in our view, they cover the major
concerns practicing clinicians have related to small-
particle aerosol therapy. To address the questions, we
scanned electronic databases (PubMed, MEDLINE,
Embase, Scopus, and Google Scholar) from the date of
inception up to December 2015 with cross-search using
the following keywords: “aerosols,” “inhalation,” “small
particles,” “fine particles,” “extrafine particles,” “chronic
obstructive pulmonary disease,” “COPD,” “asthma,” and
“inhaler.” All studies considered to be relevant for the six
questions were evaluated; no restriction was placed on
study design and language of publication.Questions
1. Is Particle Size Important to Achieve Better Lung
Deposition?
The terms and definitions used to describe the principles
of aerosol medicine and particle size are important to
mention to be able to address the question. Aerosol
particles range in size between 0.01 and 100mm.30 Because
the aerodynamic behavior of an aerosolized particle is
influenced critically by its mass, it is important to describe
the size distribution of the aerosolized particles. In clinical
studies, theMMAD and the geometric standard deviation
(GSD) often are used to characterize the dimensions of an
aerosol. The MMAD divides the aerosol size distribution
in one-half; it represents the diameter at which 50% of the
particles of an aerosol by mass are larger and 50% are
smaller.30 In general, particles with a MMAD> 5 mm arejournal.publications.chestnet.orgmost likely to deposit by impaction in the oropharynx
and be swallowed. Conversely, particles with a
MMAD < 5 mm, the so-called respirable particles, are
those with the highest probability of penetrating beyond
the oropharynx and depositing in the lungs.30 The
proportion of particles within the aerosol that are< 5 mm
is often referred to as the “fine particle fraction” or the
“fine particle dose,” if expressed in absolute mass of
drug.28 Both the particle size and fine particle fraction of
an aerosol play a significant role in the deposition of an
inhaled drug and its relative distribution within the large
and small airways.31-33 The GSD measures the dispersion
of the particle diameter and is defined as the ratio of the
median diameter to the diameter at  1 SD from the
median diameter.30 If the particle size varies over a wide
range (ie, GSD> 1.2), the aerosol is described as having a
polydisperse particle distribution; if the particles are of
similar size (ie, GSD < 1.2) the aerosol particle
distribution is described as monodisperse.30
The study of monodisperse aerosols has increased our
knowledge of the effects of particle size on regional
drug deposition in the human lung.34 Usmani et al35,36
undertook gamma scintigraphy to investigate the radio-
aerosol lung distribution of monodisperse salbutamol
particles with MMADs of 1.5-, 3.0-, and 6.0-mm sizes in
patients with mild asthma (Fig 1). The authors showed
1.5-mm particles achieved higher total lung deposition
(56% of the emitted dose) than did 3.0- and 6.0-mm
particles (51% and 46% of the emitted dose, respectively)
(Table 2).36 They also observed significantly greater
penetration into the peripheral airways with the smaller
particles. Additionally, although slow inhalation
(30L/min)was better than fast inhalation (> 60 L/min) for
effective lung deposition with 3.0- and 6.0-mm particles,
lung deposition was less affected by the differences in
inhalation flowwith 1.5-mmparticles.36 Despite the higher
deposition with 1.5-mm particles, large-particle (3.0 and
6.0 mm) salbutamol aerosols improved FEV1 more
effectively than did 1.5-mm aerosols.36 Zanen et al37 also
observed that inhalation of monodisperse salbutamol
aerosols with a MMAD of 2.8 mm caused more marked
FEV1 increases than that obtained with monodisperse
salbutamol aerosols with a MMAD of 1.5 mm.
Although these studies36,37 have improved our insights
into the effects of particle size on lung deposition and
airway function, they have assessed the effects of
treatment by using FEV1, which mainly reflects large-
airway patency. It would have been interesting to know
the results if the main outcome had been effects on small-
airway physiologic parameters, such as peripheral airway1347
Figure 1 – A-C, Oropharyngeal and posterior thorax (D-F) gamma camera images of aerosol deposition obtained by using technetium-99m-labeled
salbutamol particles of 1.5-, 3-, and 6-mm mass median aerodynamic diameter. Red areas indicate regions of highest radioactivity, and black areas
indicate regions of least radioactivity. Total lung deposition was greater with the 1.5-mm aerosols than with the 6- and 3-mm aerosols, whereas
oropharyngeal deposition increased with increasing particle size. (Adapted with permission from Usmani et al36.)resistance measured with forced oscillometry,38 air
trapping measured with body plethysmography,38
or ventilation heterogeneity measured with the single-
or multiple-breath nitrogen washout test.39,40 In addition,
both studies,36,37 investigated the effects of monodisperse
(GSD < 1.2) salbutamol, whereas commercially availableTABLE 2 ] Mean (SD) Valuesa of TLD, OD, Ex, and PI Obse
Monodisperse Salbutamol Aerosols of 1.5-, 3-, a
Asthma
MMAD, mm TLDb
1.5 56.3 (9.2)
3.0 51.0 (8.9)
6.0 46.0 (13.6)
Ex ¼ exhaled fraction data; OD ¼ oropharyngeal deposition; PI ¼ penetration in
abbreviations.
aMean (SD) FEV1 was 76.8 (11.4%) predicted value.
bValues of TLD, OD, and Ex are expressed as percentages of the delivered drug
cPI is the ratio of drug deposition in the central and peripheral areas of the lu
1348 Recent Advances in Chest Medicineaerosols are polydisperse (GSD> 1.2), consisting of a mix
of different sizes of particles. In this case, not only is
MMAD important but so is the particle size distribution
in the overall clinical effectiveness of the aerosol. Patients
should benefit the most if both the large and the small
airways are treated properly, especially in asthma, which isrved Following Inhalation of Technetium-99m-labeled
nd 6-mm MMAD in 12 Patients With Mild to Moderate
ODb Exb PIc
14.6 (4.5) 21.9 (5.7) 0.79
30.6 (7.2) 8.3 (1.5) 0.60
42.6 (14.6) 2.3 (0.1) 0.36
dex; TLD ¼ total lung deposition. See Table 1 legend for expansion of other
dose.
ng. (Modified with permission from Usmani et al.35,36)
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a disease of the whole airway tree.33 Lung deposition
images show whole airway tree targeting can be achieved
by small-particle polydisperse aerosols, but notwith large-
particle polydisperse aerosols.36
Several studies have investigated the lung deposition of
the small-particle aerosols of ICS monotherapy. The
traditional chlorofluorocarbon (CFC)-propelled pMDI
BDP suspension formulation delivers particles with a
MMAD of 3 to 4 mm, leading to approximately 15% of
the dose reaching the lung, whereas the remainder is
deposited in the oropharynx.31,32 In contrast, the newer
solution-based HFA pMDI BDP formulation delivers
particles with a MMAD of approximately 1 mm.27
Scintigraphic studies reveal that HFA BDP deposits more
than 50% of the delivered drug dose in the airways, with
effective penetration to the peripheral airways.31,32,41,42
Furthermore, althoughHFA BDP delivers particles with a
MMAD of 1 mm, it includes a range of particles allowing
some of the larger particles to deposit in both the
intermediate and large airways.31,32,41 Similarly, in
patients with mild asthma, small-particle HFA pMDI
ciclesonide solution has been shown to achieve a uniform
drug deposition in both central (44%) and peripheral
(56%) airways.43 An in vitro study44 found that different
HFA pMDIs of ICS may differ in the size of emitted
particles: budesonide, 3.5 mm; fluticasone propionate, 2.8
mm; BDP, 1.9mm; and ciclesonide, 1.9mm. Solution-based
aerosols of BDP and ciclesonide had a greater proportion
of fine particles (defined as particles < 3.1 mm) than did
the HFA pMDI suspension aerosols of budesonide and
fluticasone propionate.44
The Respimat (Boehringer Ingelheim) device is the only
soft mist inhaler currently available on the market. This
device does not require propellants because it is powered
by the energy of a compressed spring inside the inhaler.
Individual doses are delivered via a precisely engineered
nozzle system as a slow-moving aerosol cloud (hence
the term “soft mist”).22 In vitro45 and scintigraphic46
studies have shown that Respimat (Boehringer
Ingelheim International GmbH, Germany) emits a
small-particle (w 2 mm) aerosol with higher (51.6%)
levels of lung deposition, lower (19.3%) oropharyngeal
deposition, and greater peripheral lung penetration
(peripheral-to-central ratio, 1.34) than do large-particle
aerosols optimally administered from a DPI (lung
deposition, 28.5%; oropharyngeal deposition, 49.3%;
peripheral-to-central ratio, 0.95).
Deposition studies using a small-particle (1.5 mm) HFA
pMDI solution BDP/formoterol fixed-dose combinationjournal.publications.chestnet.orgin patients with asthma have shown approximately one-
third of drug is deposited in the peripheral lung region
and two-thirds is deposited in the central lung region.47
A multidose DPI device delivering small particles
(1.5 mm) of BDP/formoterol also has shown a similar
peripheral to central lung distribution.21 In contrast,
several studies show that large-particle aerosols of
fluticasone/salmeterol fixed-dose combination have poor
peripheral airway penetration.48 Taken together, lung
deposition studies conclusively demonstrate that small-
particle aerosols achieve not only better pulmonary
deposition but also effective penetration into the
peripheral areas of the lung.
2. Oropharyngeal Deposition With Small-Particle
Aerosols: Does It Matter Clinically?
The oropharyngeal 90 bend is the main determinant of
loss of inhaled drug before it reaches the lungs.34 It is
well documented31-33 that the majority of the inhaled
drug dose delivered by conventional pMDIs deposits in
the oropharynx, thus contributing to local side effects,
such as candidiasis and dysphonia for ICSs.49 In
addition, the drug deposited in the oropharynx can be
swallowed into the gastrointestinal tract and may
increase the risk of systemic adverse effects.50 In
contrast, solution-based small-particle, HFA, pMDI
aerosols deposit less drug in the oropharynx than do
large-particle aerosols.41-43 Usmani et al35 found that
1.5-mm salbutamol particles achieved lower (15%)
(Table 2) throat deposition than did 3- and 6-mm
particles (31% and 43%, respectively) (Table 2). The
lower oropharyngeal deposition of an inhaled drug
observed with a small-particle aerosol is likely to result
from the lower plume velocity observed with these
aerosols.
The reduction in oropharyngeal deposition with small-
particle ICS aerosols has clinical implications for local
and systemic side effects. In patients with moderate to
severe asthma, Bateman et al51 observed a significantly
lower rate of oral adverse events (candidiasis and
dysphonia) with small-particle ciclesonide aerosol than
with large-particle fluticasone propionate aerosol. In
patients with mild asthma, Newman et al43 observed a
low (approximately 33%) oropharyngeal deposition and
high (approximately 52%) lung deposition with small-
particle pMDI ciclesonide aerosol. Even when one-half
of the drug dose targeted the distal lung region, this did
not translate into greater pulmonary bioavailable
adverse effects.41 In this regard, Derom et al52,53 found
that small-particle ciclesonide aerosols (320 or 640 mg1349
daily) did not cause significant suppression of 24-hour
urinary cortisol levels in contrast to findings with
large-particle fluticasone propionate aerosols (500 or
1,000 mg daily). Both ICS treatments decreased airway
hyperresponsiveness to adenosine monophosphate,52
and methacholine.53 Thus, in this scenario, the
therapeutic ratio (ie, the clinical benefit vs the adverse
effects) actually may be improved with small-particle
aerosols of ciclesonide.
With respect to ICS/LABA treatment, Huchon et al24
showed that morning urinary cortisol was significantly
higher after inhalation of the small particles of an HFA
pMDI BDP/formoterol fixed-dose combination (400 mg/
24 mg daily, respectively) than after inhalation of the
large particles of CFC pMDI BDP at the dose of 1,000 mg
daily together with CFC pMDI formoterol at 24 mg daily.
Furthermore, treatment with small-particle aerosols
achieved significantly better levels of asthma control,24
thus supporting the concept of an improved therapeutic
ratio. In summary, compared with large-particle
aerosols, small-particle aerosols result in lower
oropharyngeal deposition, fewer local side effects, and
less systemic absorption from the swallowed dose.
3. Does Exhalation of Drug Matter With Small-
Particle Aerosols?
The inspiratory maneuver is a key determinant for the
penetration and deposition of drug particles into the
airways and, thus, the dose delivered to the target site.32
Particles that are not deposited may be exhaled.32
Previous in vitro modeling studies27,54,55 showed a large
(approximately 80%) proportion of inhaled small
particles could be exhaled because they were able to
remain airborne for a considerable time, even with a
breath-hold pause maximizing the effect of gravitational
sedimentation.35 Particles that remain airborne in the
larger airways are likely to be exhaled because of a
greater settling distance before coming into contact with
the airway walls. However, these in vitro modelingTABLE 3 ] Percentage of Ex Observed With ICSs of Differe
ICS MMAD, mm
Ciclesonide HFA pMDI 1.1
BDP HFA pMDI 1.1
BDP/formoterol DPI 1.5
BDP CFC pMDI 3.5
Fluticasone CFC pMDI 2.4
Budesonide DPI 3.7
CFC ¼ chlorofluorocarbon. See Table 1 and 2 legends for expansion of other a
1350 Recent Advances in Chest Medicinestudies27,54,55 did not account for features of inhaled
drug delivery in vivo that can affect aerosol deposition in
the lungs, such as the breath-hold pause that retains
most particles within the airways or the effect of
different inhalation maneuvers when using pMDIs or
DPIs. In their in vivo study, Usmani et al36 found that,
although the exhaled fraction of a monodisperse
salbutamol aerosol increased with the decreasing particle
size (Table 2), the small particles were exhaled far less
than previously predicted by in vitro models. Studies
performed in both healthy subjects31,33,56 and patients
with asthma,21,43,44 using commercial polydisperse
aerosols, showed that the exhaled fraction of small-
particle ICS aerosols was similar to that observed with
large-particle aerosols, ranging between 2% and
14% (Table 3). In conclusion, small-particle aerosols are
not exhaled to any significantly greater level than are
large-particle aerosols when assessed using in vivo lung
deposition studies.
4. Are Small-Particle Aerosols More Effective Than
Large-Particle Aerosols?
Several studies have shown that small-particle aerosols
improve markers of small-airway dysfunction and
inflammation in both asthma and COPD.13-15,57,58
However, the question remains59 as to whether
treatment with small-particle aerosols leads to added
benefit in patients with asthma or COPD when
compared directly with large-particle aerosols. Few
studies have compared the effect of the same drug
delivered as a small- or a large-particle aerosol. Such
head-to-head comparisons are limited to CFC-driven
vs HFA-driven BDP, but with the CFC propellants no
longer available, additional comparisons cannot be
made. Findings from studies comparing different drugs
delivered by different inhaler devices are difficult to
interpret. In addition, the lack of direct comparison of
small- vs large-particle aerosol therapies using the same
ICS also may influence the validity of equivalent dosages
reported by current guidelines.60nt Sizes
Ex Reference
3.70 Newman et al43
6.0, 14.0 Leach et al31,33
3.30 Corradi et al21
3.0 Leach et al31,33
2.0 de Vries et al44
1.0 Warren et al56
bbreviations.
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A recent review of the literature14 revealed that, in
controlled clinical trials involving highly selected adult
patients with asthma who fulfilled precise inclusion and
exclusion criteria, treatments with small-particle
aerosols achieved efficacy similar to that of large-particle
aerosols. However, patients enrolled in controlled
clinical trials may not represent the heterogeneity of
patients with asthma seen in real-life daily clinical
practice.61 As little as 6% of real-life patients with
asthma fit the criteria of controlled clinical trials, which
calls into question the application of clinical trial results
to patients seen in daily clinical practice.62 The same
review found that, in real-life asthma studies, treatment
with small-particle aerosols resulted in greater daily
asthma control; better quality-of-life indexes; and,
importantly, lower daily ICS dose, when compared with
large-particle aerosol treatment.14 Recently, the
effectiveness of small-particle ICS pMDI therapy was
compared with that of large-particle ICS treatment in
children with asthma who were either initiating or
stepping up ICS therapy.63 Over 1 year, small-particle
ICS was more effective than large-particle ICS for
asthma control and as effective as adding a LABA in a
fixed-dose combination inhaler.63 Noticeably, the
differential effects of small- vs large-particle ICS were
more pronounced in younger than in older children.63
The key studies comparing the effects of small-particle
aerosols vs large-particle aerosols in adult patients with
asthma or COPD are reported in e-Tables 1-3.
In summary, randomized controlled trials show small-
particle aerosols are as effective as large-particle
aerosols. However, real-life studies reveal small-particle
aerosols are more efficacious in patients’ reported
outcomes than are large-particle aerosols at much lower
daily ICS doses.5. Do Small-Particle Aerosols Cause More Adverse
Effects Than Do Large-Particle Aerosols?
Data obtained from large-scale asthma studies showed
that the overall incidence of at least one adverse event
was significantly lower in patients treated with small-
particle HFA, pMDI, BDP aerosols (46%) than in
patients receiving the same drug as large-particle
aerosols (59%) and was equal to that of HFA placebo
(51%).64,65 Most adverse events were reported as mild to
moderate. Administration of high doses (up to 1,000 mg/
60 mg) of small-particle BDP/formoterol aerosol
combination delivered by means of HFA pMDI was well
tolerated, with a safety profile generally similar to that of
formoterol alone.66journal.publications.chestnet.orgIncreased distal lung deposition of ICS might be
expected to be associated with increased systemic effects,
particularly the suppression of cortisol production.
However, reassuringly, data from clinical trials have
not documented any increased risk of systemic effects
with an inhaled small-particle ICS formulation64,65,67-69
or a small-particle ICS/LABA combination
formulation.66,70,71 Treatment with small-particle HFA
pMDI, ICS/LABA, solution-based aerosols has resulted
in less suppression of the hypothalamic-pituitary-
adrenal axis, as assessed by means of cortisol levels, than
has treatment with an equipotent dose of large-particle
CFC, pMDI ICS plus LABA.72 However, because ICSs
may differ substantially in their gastrointestinal
bioavailability, findings from one drug should be
generalized with caution to other drugs. The available
data suggest that the more distal deposition of small-
particle formulations of ICS are safe in patients with
asthma, and, for some drugs, may even result in a
reduced effect on the hypothalamic-pituitary-adrenal
axis, probably through less oropharyngeal deposition
and, hence, decreased gastrointestinal bioavailability.
6. Do You Need to Add a Spacer to Small-Particle
Aerosol Devices or Use a Different Inhaler
Technique Than With Large-Particle Aerosol
Devices?
A spacer is an extension device placed at the interface
between the patient and the pMDI.73,74 Valved holding
chambers (VHCs) have a one-way valve at the
mouthpiece to prevent exhalation into the chamber and
to allow the patient to breathe from a “standing aerosol
cloud,” thus reducing the need of breath-hand
coordination.73,74 Both spacers and VHCs are used with
pMDIs to increase the efficiency of aerosol delivery.73,74
They reduce the aerosol speed and allow for the
evaporation of propellant from larger droplets thereby
reducing oropharyngeal deposition and increasing deep
lung deposition.73,74 Some VHCs, such as the
AeroChamber Plus Flow-Vu (Monaghan Medical
Corporation), can indicate whether the patient is
inhaling correctly by means of a whistle when the
patient is inhaling too quickly.74
In theory, the use of small-particle aerosol therapy
should reduce the need for a spacer device or a VHC
because they have (1) a lower impact force on the back
of the patient’s throat, (2) a slower plume, (3) a
longer time for particle evaporation, and (4) reduced
throat deposition.19 Because of their less forceful spray
and softer plume, small-particle aerosols may deposit a
smaller amount of drug into the spacer walls, with a1351
TABLE 4 ] Key Aspects and Contrasting Points Related to Small-Particle Aerosols
Question Key Point, Contrast, or Observation
Is particle size important to achieve better lung deposition?  Particle size markedly influences the deposition of an
inhaled drug and its relative distribution within the large
and small airways.
 Small-particle aerosols improve drug deposition and
regional airway distribution within the lungs.
Oropharyngeal deposition with small-particle aerosols: does
it matter clinically?
 Drug deposition at the oropharyngeal level is lower with
small-particle aerosols than with large-particle aerosols.
Does exhalation of drug matter with small-particle aerosols?  In in vivo lung deposition studies, small-particle aerosols
are not exhaled to any greater significant level than are
large-particle aerosols.
 In vitro studies previously suggested exhalation of small
particles did not model therapeutic aerosol inhalation with
a breath-hold pause.
Are small-particle aerosols more effective than large-
particle aerosols?
 In randomized controlled clinical trials, small-particle
aerosols are as effective as large-particle aerosols.
 In real-life studies, small-particle aerosols are more
efficacious in patients’ reported outcomes than are large-
particle aerosols.
 Studies comparing the same drug inhaled as small-or
large-particle aerosol are limited essentially to BDP
delivered as a CFC or HFA formulation.
Do small-particle aerosols cause more adverse effects than
do large-particle aerosols?
 The use of small-particle aerosols is safe in patients with
asthma and might result in a reduced effect on the
hypothalamic-pituitary-adrenal axis, probably through
less oropharyngeal deposition and hence decreased
gastrointestinal bioavailability.
 Local oropharyngeal adverse effects are fewer with small-
particle aerosols.
 Comparisons of the systemic effects of ICSs have been
performed mainly with ICSs that have a high gastroin-
testinal bioavailability. More studies are needed with ICSs
with low gastrointestinal bioavailability.
Do you need to add a spacer to small-particle aerosol
devices or use a different inhaler technique than with
large-particle aerosol devices?
 The use of spacers or holding chambers with pMDIs
delivering small-particles aerosols reduces throat
deposition and improves drug delivery to the lungs.
 This can be a valuable option for patients with difficulties
achieving an adequate inhalation technique.
 Studies are needed to assess whether the beneficial
effects are due to a better inhalation technique when a
spacer is used.
See Table 1 and 3 legends for expansion of abbreviations.consequent increase in lung deposition. Roller et al75
found that inhalation of small-particle BDP aerosol
delivered via an HFA pMDI with the AeroChamber
Plus VHC resulted in high lung deposition and
marked decrease in oropharyngeal deposition,
compared with the same formulation inhaled via the
pMDI alone. Recently, a small-particle flunisolide
aerosol delivered by an HFA pMDI with a built-in
spacer has been introduced in the market for asthma
treatment. This formulation enhances the pulmonary/
oropharyngeal deposition ratio further compared
with that of the traditional formulation without a
spacer.761352 Recent Advances in Chest MedicineThe increased drug deposition in the lungs with spacers
or VHCs added to pMDIs delivering small-particle
aerosols may raise concerns about the possibility of
increased systemic exposure to drugs, especially ICS (see
also question 5). However, studies performed in both
healthy subjects and patients with asthma show that this
does not seem to be the case. Singh et al77 found in
healthy volunteers that adding the AeroChamber Plus
VHC to an HFA pMDI delivering small-particle BDP/
formoterol aerosol did not affect the systemic exposure
of these drugs compared with pMDI alone. Similar
results were obtained in adolescents with asthma.78 The
results of these studies are particularly relevant because[ 1 5 1 # 6 CHES T J U N E 2 0 1 7 ]
they suggest that the use of pMDIs delivering small-
particle aerosols in conjunction with the AeroChamber
Plus VHC does not affect the safety profile of the
product. More studies with other drugs are needed.
In summary, addition of spacers or VHCs to pMDIs
delivering small-particle aerosols further reduces throat
deposition and improves drug delivery to the lungs.
Adding VHCs to small-particle-based pMDIs can be a
valuable option for certain patient groups, such as those
with difficulties in achieving an adequate inhalation
technique.
Summary and Conclusion
A summary of key points and contrasts related
to the various questions is reported in Table 4.
Pathophysiologic evidence for small-airway dysfunction
and the clinical emergence of a small-airway phenotype
suggest that we should consider treating the small-
airway region when reviewing patients with asthma or
COPD clinically. In view of the increasing recognition
of the role of small airways in asthma and COPD,3,4
it is not unexpected that small-particle aerosols are
beginning to show a greater impact than traditional
large-particle aerosols on asthma and COPD outcomes.
A recent review14 of the available literature suggests that,
in randomized controlled trials, small-particle aerosol
therapy is as good as large-particle aerosol therapy.
However, none of these randomized trials selected
patients with documented baseline distal airway
dysfunction, in whom the effects of a targeted small-
particle aerosol treatment potentially could be larger.
The findings of recent studies13-15 focusing on small
airways should be confirmed in large trials in patients
with different patterns of severity and control. More
importantly, through real-life studies, it is becoming
evident that small-particle aerosol therapy has
advantages over large-particle therapy that are relevant
to our daily practice, as opposed to findings in
selective populations entered into randomized clinical
trials.61,62
Definitive answers to the questions posed in this article
are yet to be established fully and will require
collaboration and participation among academics and
the pharmaceutical industry specifically to undertake
head-to-head trials of small- vs large-particle aerosol
therapy truly to inform us whether small-particle
therapy will be useful to practicing clinicians. In
addition, performing trials exploring potential
phenotypic differences in response to small- orjournal.publications.chestnet.orglarge-particle aerosols would be important. There have
been multiple strong calls to action to undertake
definitive clinical trials in this area,15,79-81 and now is the
time to conduct these definitive studies. The respiratory
care community needs to make a concerted effort to
convince funding agencies to provide support for these
much needed studies and to convince the
pharmaceutical industry to supply the same
corticosteroids in large- and small-particle formulations
to make these studies feasible.
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